Skip to content
Review Open access

Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood–Brain Barrier for Advanced Theranostics

Sep 2026 · AAPS PharmSciTech · Vol 27 · 0 citations · 191 references
Medicine

TL;DR

This review critically examines advanced surface functionalization strategies, including chemical functionalization (amine, thiol, carboxyl groups), ligand conjugation (antibodies, aptamers, peptides), and polymeric coatings that enhance BBB penetration, facilitate tumor-specific targeting, and enable stimuli-responsive drug release.

Abstract

Brain tumors, particularly glioblastoma multiforme (GBM), remain among the most lethal forms of cancer due to their aggressive nature and the formidable challenge posed by the blood–brain barrier (BBB), which restricts the delivery of therapeutic agents. Conventional treatment modalities, including surgery, radiotherapy, and chemotherapy, often fail to achieve effective and targeted therapy without inducing systemic toxicity or damaging healthy brain tissue. In recent years, mesoporous silica nanoparticles (MSNs)have emerged as a versatile platform for targeted brain tumor therapy because of their high surface area, tunable pore structure, biocompatibility, and ease of surface functionalization. This review critically examines advanced surface functionalization strategies, including chemical functionalization (amine, thiol, carboxyl groups), ligand conjugation (antibodies, aptamers, peptides), and polymeric coatings (PEG, chitosan, PLGA) that enhance BBB penetration, facilitate tumor-specific targeting, and enable stimuli-responsive drug release (different types of exogenous and endogenous). We also explore the interactions of these modifications with key signaling pathways (e.g., Wnt/β-catenin, PDGF-B, TGF-β) that regulate BBB integrity and glioma progression. Special emphasis is placed on how surface-engineered MSNs can improve site-specific drug delivery, increase therapeutic accumulation in brain tumor tissue, and minimize off-target toxicity. Despite the considerable promise demonstrated by these techniques in preclinical glioma models, obstacles such as scalable synthesis, regulatory compliance, and long-term biosafety must be addressed to facilitate clinical translation. This review focuses specifically on brain tumor targeting via functionalized MSNs and provides mechanistic insights while highlighting emerging strategies to advance MSNs as next-generation therapeutics for brain tumor treatment.

Read PDF

Similar papers

Review Open access Sep 2026

Next-Generation Liposomal and Nanoparticle-Based Systems for Glioblastoma: Molecular Targeting Strategies to Overcome the Blood–Brain Barrier

Glioblastoma (GBM) remains one of the most lethal and intractable central nervous system malignancies, characterized by aggressive cellular proliferation, profound hypoxia, and an immunosuppressive microenvironment. The primary pharmacokinetic obstacle for systemic interventions is the blood–brain barrier (BBB), which...

Joaquin Fiallo Arroyo, Bernardo Castellón, Jose E. Leon-Rojas · 0 citations
Aug 2026

Polyphenol-engineered selenium nanocatalysts enable neuroprotective glioblastoma chemoimmunotherapy via nose-to-brain delivery.

Glioblastoma therapy is severely limited by poor blood-brain barrier (BBB) penetration and systemic toxicity of chemotherapeutics. Here, we engineered polyphenol-stabilized selenium nanoparticles (nGPSe NPs, <60 nm) via spatial confinement synthesis as a redox-dual nanocatalytic carrier for afatinib (AFA). These AFA@nG...

Shunming Hong, Rong Hu, Qing-Bin Nie et al. · 0 citations
Review Sep 2026

Nanoparticle-mediated Therapeutic Inventions against Glioblastoma: A Narrative Review on Current Perspectives.

Glioblastoma (GB) is a highly aggressive tumor that demonstrates significant treatment resistance due to the blood-brain barrier (BBB) and resistance mechanisms of the tumor. Nanoparticle- based drug delivery systems (NDDS) can enhance drug bioavailability, enable targeted delivery, and provide controlled release. Thes...

Bida Joshua John, Dauda Maibasha, Ratnakar Shukla et al. · 0 citations
Review Aug 2026

Dendrimer-Based Nanoplatforms for Cancer Diagnosis and Therapy: from Liquid Biopsy to Targeted Protein Degradation

Dendrimer-based systems have shown considerable potential to remodel the tumor microenvironment, induce immunogenic cell death, enhance immune activation, and facilitate combination therapies, offering promising opportunities to improve cancer diagnosis, treatment, and patient outcomes.

Mahsa Hasannejad Alibaglou, Zeinab Chaharlashkar, Fateme Bina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.